Mode
Text Size
Log in / Sign up
N/A N=15 Single-blind Treatment

Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Facial Wrinkles

Rhytides · Wrinkle

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Sep 2023
Primary outcome: Primary: Change in Facial Wrinkles at 12 Weeks Post Final Treatment Compared to Baseline — -0.10 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Venus Viva (Device)
Age
Adult, Older Adult · 22+ yrs
Sex
All
Sponsor
Venus Concept
Primary completion
Aug 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Facial Wrinkles at 12 Weeks Post Final Treatment Compared to Baseline
-0.10
SECONDARY
Subject Satisfaction
2.5
SECONDARY
Subject Scale - Visual Analog Scale for Pain
3.2
SECONDARY
Subject Scale - 5 Point Scale for Treatment Tolerability
3.55

Summary

Prospective, single centre, evaluator-blind study of the safety and performance of fractional radiofrequency (RF) for the treatment and reduction of facial wrinkles.

Eligibility Criteria

Inclusion Criteria

  • Healthy, male or female subjects over 21 years of age who are seeking treatment and reduction of their facial wrinkles.
  • Able to read, understand and voluntarily provide written Informed Consent.
  • Able and willing to comply with the treatment/follow-up schedule and requirements.
  • Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study and have a negative Urine Pregnancy test at baseline.

Exclusion Criteria

  • Implantable defibrillators, cardiac pacemakers, and other metal implants
  • Subjects with any implantable metal device in the treatment area
  • Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).
  • Permanent implant in the treated area, such as metal plates and screws, or an injected chemical substance.
  • Current or history of any kind of cancer, or pre-malignant moles.
  • Severe concurrent conditions, such as cardiac disorders.
  • Pregnancy or intending to become pregnant during the study and nursing.
  • Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications.
  • History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only after a prophylactic regime has been followed for 2 weeks or longer prior to enrollment, or according to Investigator's discretion.
  • Poorly controlled endocrine disorders, such as diabetes.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  • History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.
  • History of bleeding coagulopathies, or use of anticoagulants (excluding daily aspirin).
  • Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if face is treated.
  • Use of isotretinoin (Accutane®) or other systemic retinoids within six months or topical retinoids within three months prior to treatment; or as per physician's discretion.
  • Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g. ibuprofen-containing agents) one week before and after each treatment session.
  • Any surgical procedure in the treatment area within the last six months or before complete healing.
  • Treating over tattoo or permanent makeup.
  • Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.
  • As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03831477). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search